

RESPIRATION Day 2026

The aim of the 2026 Edition of “Respiration Day” is to provide the view of where the respiratory clinicians and researchers are and where they are heading in the field of chronic respiratory diseases, particularly Chronic Obstructive Pulmonary Disease (COPD), asthma, bronchiectasis and their comorbidities, and the role of small airway diseases in these respiratory diseases. The invited members of the faculty are among the most productive international clinical scientists in the field chronic airway diseases, the audience will be 350 national top national clinical opinion leaders selected from more than 20 countries. The main aim of the meeting is educational, and the speakers have been specifically invited to translate in their lectures the most important recent discoveries to the potential improvement of clinical practice. A significant proportion of time (40%) will be devoted to discussion. The meeting is divided in 5 sessions.

The first session will focus on the recent advancements in COPD and its comorbidities, and in particular the first lecture will focus on the need to better characterize the different phenotypes included under the umbrella of the term COPD, both in term of etiology and clinical presentation, early diagnosis, and active search of multimorbidity to improve the management of

individual patients (Bhatt et al, 2025; Celli et al, 2022). The second lecture will be devoted to novel therapies for COPD, particularly the biologics, with the aim of improved comprehensive and personalized management (Agusti et al, 2025). The third lecture will focus on the major cardiovascular risk in patients with COPD, both in stable and during and in the aftermath of exacerbations of respiratory symptoms (Gale et al, 2025).

The second session will focus on asthma as a disease of both central and peripheral airways (Siddiqui et al, 2026), the need of integration of traditional pharmacological inhalation treatments with systemic agents and/or biologics (Porsbjerg et al, 2023), the third the ongoing research focused on mechanisms rather than clinical treatable traits (Gaberino et al, 2026).

The third session will be devoted to the importance and impact of small airways dysfunction for chronic airway diseases, and in particular on the fundamental role of inhalers but also of their environmental impact, its complex impact on respiratory and non-respiratory components of chronic airway diseases, and last, but not least, how can AI help us to understand the role of small airways dysfunction.

The fourth session will be devoted to the novel discoveries in the field of pathology of chronic airway diseases, and particularly the importance of mucus plugs, and mucociliary clearance.

Finally the fifth session will be devoted to bronchiectasis that in the last 15 years has been discovered to represent not only a treatable trait of other chronic airway diseases but also an independent treatable disease (Burgel and Mall, 2026; Chalmer et al, 2025).

CREDITS

ITALIAN CME CREDITS:

ITALIAN TARGET AUDIENCE:

Profession: Physician
Disciplines: Allergology and clinical immunology; Geriatrics; Respiratory diseases; General medicine (Family Practitioners); Internal Medicine; Occupational medicine and workplace safety.

The event (246-482645) has been accredited with **3 Italian CME credits** that will be granted to those participants who attend at least 90% of scientific works, fill in the questionnaire assessment of perceived quality.

Organizing secretariat:



CHORUS S.p.A. - Via G. Mazzini, 33 - 20099 Sesto San Giovanni (MI)
Tel: +39 02 244491 - info@respirationday.com - www.respirationday.com

Seguici su:

Supported by an unconditioned grant from:



UEMS-EACCME ACCREDITATION:

An application has been made to the UEMS EACCME® for CME/CPD accreditation of this event.

CME Provider:



DOC CONGRESS S.r.l. - ID 246 Albo Provider Agenas
info@respirationday.com - www.respirationday.com

Seguici su:

With the patronage of:



RESPIRATION Day 2026



CHRONIC AIRWAY DISEASES AND THEIR COMORBIDITIES

Parma, 26-27 June 2026

Starhotels Du Parc
Viale Piacenza, 12/c

www.respirationday.com

SCIENTIFIC REFEREES:

Prof. Dario Olivieri,
Professor of Respiratory Disease, University of Parma, Italy

Prof. Gaetano Caramori,
Full Professor of Respiratory Diseases, University of Parma, Italy

FACULTY:

Alvar Agusti, Barcelona (Spain)

Stefano Aliberti, Milan (Italy)

Surya Bhatt, Birmingham (USA)

Matteo Bonini, Rome (Italy)

Guy Brusselle, Ghent (Belgium)

Pierre-Régis Burgel, Paris (France)

Gaetano Caramori, Parma (Italy)

Carlo Castellani, Genoa (Italy)

Bartolome Celli, Boston (USA)

Alfredo Chetta, Parma (Italy)

Marco Contoli, Ferrara (Italy)

Filippo Crea, Rome (Italy)

Alejandro A. Diaz, Boston (USA)

Leonardo Fabbri, Ferrara (Italy)

John Fahy, San Francisco (USA)

Pieter Goeminne,
Sint-Niklaas (Belgium)

Lies Lahousse, Ghent (Belgium)

Paolo Martelli, Parma (Italy)

Dario Olivieri, Parma (Italy)

Klaus Rabe, Kiel (Germany)

Paola Rogliani, Rome (Italy)

Michal Shteinberg, Haifa (Israel)

Omar Usmani, London (UK)

Maarten Van Den Berge,
Groningen (Netherlands)

Erika Von Mutius, Munich (Germany)

Min Zhang, Shanghai (China)

26 June 2026

07:45 Registration of the delegates

08:15 Welcome Session
Prof. Dario Olivieri,
*Professor of Respiratory Disease,
University of Parma, Italy*

Prof. Gaetano Caramori,
*Full Professor of Respiratory Diseases,
University of Parma, Italy*

Prof. Paolo Martelli,
Rector of the University of Parma, Italy

Session 1
Chronic Obstructive Pulmonary Disease (COPD) as pulmonary component of multimorbidity
Chairpersons: Paola Rogliani, Leonardo M. Fabbri

09:00 Novel approaches to the diagnosis and assessment of severity of multimorbid COPD - **Surya Bhatt**

09:25 Novel approaches to the pharmacologic management of multimorbid COPD - **Bartolome Celli**

09:50 Cardiovascular risk in stable and exacerbated multimorbid COPD - **Filippo Crea**

10:15 Discussion

11:00 *Coffee break*

Session 2
Asthma as a disease of central and peripheral airways
Chairpersons: Alfredo Chetta, Klaus Rabe

11:30 Pulmonary pathology of asthma, COPD and chronic bronchitis: role of small airways - **Guy Brusselle**

11:55 Integrated pharmacologic and biologic treatment of severe asthma - **Matteo Bonini**

12:20 Mechanism directed treatment in chronic airway diseases - **Klaus Rabe**

12:55 Discussion

13:30 *Lunch*

Session 3
Small airways dysfunction in chronic airway diseases
Chairpersons: Marco Contoli, Lies Lahousse

14:30 Early origins of asthma: what happens to the airways? - **Erika Von Mutius**

14:55 Pathophysiology of Small Airway Diseases (SAD) - **Omar Usmani**

15:20 Artificial intelligence in Chronic Airway Diseases
Alvar A Agusti

15:55 Discussion

16:40 *Coffee break*

17:00 *End of Day 1*

27 June 2026

Session 4
Mucus and mucociliary clearance in chronic airway diseases
Chairpersons: Pierre-Régis Burgel, Min Zhang

09:00 Clinical role of central and peripheral airway diseases in asthma - **Maarten Van den Berge**

09:25 Mucus plugs in chronic airway diseases
Alejandro A. Diaz

09:50 The pathobiology and treatment of mucus plugs in asthma and COPD - **John Fahy**

10:15 Discussion

11:00 *Coffee break*

Session 5
Bronchiectasis as treatable trait of chronic airway diseases or as an independent disease entity
Chairpersons: Pieter Goeminne, Carlo Castellani

11:30 Novel approaches to the diagnosis and assessment of severity of bronchiectasis - **Stefano Aliberti**

11:55 Novel approaches to the pharmacologic management of bronchiectasis - **Michal Shteinberg**

12:20 Mechanism directed treatment approach: triple therapy in cystic fibrosis - **Pierre-Régis Burgel**

12:55 Discussion

13:30 Take-home messages and conclusions

13:40 Lunch

